10-Q: Cue Biopharma Reports Q3 2024 Results, Prioritizes Autoimmune Programs

Cue Biopharma announced its third quarter 2024 results, highlighting a strategic shift towards autoimmune programs while continuing to monitor oncology assets.

Summary

• Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing T-cell modulating therapeutics.
• The company is shifting its focus to autoimmune programs, CUE-401 and CUE-501, while seeking partnerships for its oncology programs, CUE-101 and CUE-102.
• For the three months ended September 30, 2024, collaboration revenue was $3.3 million, compared to $2.1 million in the same period of 2023.
• The net loss for the quarter was $8.7 million, compared to a net loss of $11.0 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, collaboration revenue was $7.7 million, compared to $3.7 million in the same period of 2023.
• The net loss for the nine months was $31.2 million, compared to a net loss of $37.3 million in the same period of 2023.
• As of September 30, 2024, the company had $32.4 million in cash and cash equivalents.
• The company believes its current cash will fund operations into the fourth quarter of 2025, but additional capital will be needed.
• A public offering in September 2024 generated net proceeds of $10.8 million.
• The company has a loan agreement with First Citizens Bank with an outstanding principal of $5.0 million as of September 30, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive clinical data and increased collaboration revenue, the company's financial situation and need for additional funding create uncertainty. The strategic shift to autoimmune programs is a positive development, but the deprioritization of oncology programs is a concern.

Positives

• Collaboration revenue increased significantly year-over-year, driven by the Ono collaboration.
• The company's net loss decreased compared to the same periods in the previous year.
• Clinical data for CUE-101 shows promising results, including increased overall survival and response rates.
• CUE-102 has demonstrated anti-tumor activity in multiple cancer types.
• Preclinical data for CUE-401 and CUE-501 supports their potential in treating autoimmune diseases.
• The company successfully raised $10.8 million through a public offering in September 2024.
• The company has a strategic collaboration with Ono to develop CUE-401.

Negatives

• The company has a history of operating losses and negative cash flows.
• The company's recurring losses raise substantial doubt about its ability to continue as a going concern.
• The company is dependent on raising additional capital to fund its operations.
• The company has deprioritized its oncology programs, CUE-101 and CUE-102, which were previously the focus of its resources.
• The company is relying on third-party support to further develop its oncology programs.
• The company has a loan agreement that restricts its operating and financial flexibility.
• The company is subject to the risk of delisting from Nasdaq if it fails to comply with listing requirements.

Risks

• The company is a clinical-stage biopharmaceutical company with no history of generating commercial revenue.
• The company is substantially dependent on the success of its drug product candidates.
• The company has limited experience in conducting clinical trials and no history of commercializing biologic products.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company relies on third parties to conduct clinical trials and manufacture drug supplies.
• The company may not be able to protect its intellectual property.
• The company will need substantial additional financing to support its growth and ongoing operations.
• The company's recurring losses from operations raise substantial doubt regarding its ability to continue as a going concern.
• The company has a loan agreement that requires it to meet certain operating covenants and places restrictions on its operating and financial flexibility.
• The company is subject to the risk of delisting from Nasdaq if it fails to comply with listing requirements.

Future Outlook

The company expects its current cash to fund operations into the fourth quarter of 2025, but will need to raise additional capital. The company plans to continue the preclinical development of CUE-401 and CUE-501 and seek partnerships for its oncology programs. The company anticipates selecting a clinical candidate and initiating IND-enabling studies for CUE-401 in the first half of 2025 and providing a CUE-501 program update in the fourth quarter of 2024.

Management Comments

• The company is strategically prioritizing its autoimmune programs.
• The company is actively pursuing third-party support for its oncology programs.
• The company believes its Immuno-STAT platform has the potential for delivering a diverse and expanding pipeline of promising drug product candidates.
• The company intends to optimize the value and probability of commercialization of its Immuno-STAT drug product candidates by utilizing a diverse, strategic approach of partnering certain programs, while retaining control and upside potential of others.

Industry Context

The shift towards autoimmune programs reflects a growing interest in this therapeutic area, while the company's continued focus on T-cell modulation aligns with broader trends in immuno-oncology and autoimmune disease treatment. The company's approach to selectively target specific T-cells is a key differentiator in a competitive landscape.

Comparison to Industry Standards

• The observed objective response rate (ORR) of 46% in the CUE-101 combination trial is significantly higher than the historical ORR of 19% observed with KEYTRUDA alone in the KEYNOTE-048 study, suggesting a potential improvement in efficacy.
• The median overall survival (mOS) of 21.8 months in the CUE-101 combination trial compares favorably to the historical mOS of 12.3 months with KEYTRUDA alone, indicating a potential survival benefit.
• The mOS of 20.8 months in the CUE-101 monotherapy trial is also higher than the historical mOS of 8.4 months with KEYTRUDA and 7.5 months with OPDIVO in the 2L setting, suggesting a potential improvement in survival.
• The 40% reduction in tumor burden observed in a pancreatic cancer patient treated with CUE-102 is a positive signal, although further data is needed to confirm its clinical significance.
• The company's approach to selectively redirecting memory T cells to deplete B cells in autoimmune diseases is similar to the approach used in CD19-CAR-T cell therapy, but with the potential advantages of an off-the-shelf biologic.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may experience dilution due to potential future equity offerings.
• Employees may be affected by the company's organizational restructuring and workforce reduction.
• Customers and partners may be impacted by the company's strategic shift and prioritization of autoimmune programs.
• Creditors may be affected by the company's financial situation and need for additional funding.

Next Steps

• The company will continue to monitor the maturing data from its CUE-101 and CUE-102 clinical trials.
• The company will seek third-party support through partnerships and collaborations to further develop the CUE-100 series programs.
• The company anticipates selecting a clinical candidate and initiating IND-enabling studies for CUE-401 in the first half of 2025.
• The company expects to provide a CUE-501 program update in the fourth quarter of 2024, with lead candidate selection anticipated in the first quarter of 2025.

Key Dates

Keywords

Immuno-STAT, T-cell engagers, oncology, autoimmune, CUE-101, CUE-102, CUE-401, CUE-501, clinical trials, biopharmaceutical, regulatory T cells, cancer, immunotherapy